secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2024-02-09T23:59:59+00:00
Accession:  0001193125-24-029913
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics Chief Legal Officer Tamara Joseph to depart March 6, 2024
----------------------------------------------------------------------------

- Tamara Joseph, Chief Legal Officer and Corporate Secretary, is leaving effective March 6, 2024 to pursue other interests.
- Severance includes continuation of base salary for nine months totaling $356,298.75, plus prorated cash bonus of $34,266.98.
- Joseph will provide consulting services on an hourly as-needed basis for nine months at $395/hour; stock options and RSUs continue vesting.
- Separation and Consulting Agreement entered February 9, 2024; full terms to be filed with Form 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524029913/0001193125-24-029913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524029913/d45988d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-029913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer